KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Issued (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Shares Issued data on record, last reported at $553000.0 in Q4 2025.

  • For Q4 2025, Shares Issued rose 266.23% year-over-year to $553000.0; the TTM value through Dec 2025 reached $2.0 million, up 69.84%, while the annual FY2025 figure was $2.0 million, 69.84% up from the prior year.
  • Shares Issued reached $553000.0 in Q4 2025 per AMRX's latest filing, down from $653000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $685000.0 in Q2 2025 and bottomed at $5000.0 in Q2 2021.
  • Average Shares Issued over 5 years is $298823.5, with a median of $153000.0 recorded in 2021.
  • The widest YoY moves for Shares Issued: up 13420.0% in 2021, down 96.73% in 2021.
  • A 5-year view of Shares Issued shows it stood at $19000.0 in 2021, then skyrocketed by 2126.32% to $423000.0 in 2022, then crashed by 89.83% to $43000.0 in 2023, then surged by 251.16% to $151000.0 in 2024, then skyrocketed by 266.23% to $553000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $553000.0 in Q4 2025, $653000.0 in Q3 2025, and $685000.0 in Q2 2025.